Highlights

  • Revenue increased 22% to AUD 13.8 million for the 10 months to April 30, 2026, compared to AUD 11.3 million in the prior corresponding period.
  • EBITDA grew 28% to AUD 3.4 million with EBITDA Margin expanding to 25%, and NPAT increased 28% to AUD 1.9 million, with a record EBITDA month recorded in April 2026.
  • The NAB Debt Facility was refinanced in May 2026 on a four-year term to 2030, with approximately AUD 1.0 million of principal repaid to date, reducing the outstanding balance to AUD 5.6 million.

 

Shares in Cryosite Limited (ASX:CTE) released a trading update covering the 10 months to April 30, 2026. The stable share price reflects the market's familiarity with Cryosite's consistent financial performance trajectory, with the disclosed metrics — 22% revenue growth and 28% EBITDA growth — representing a continuation of a trend that investors have been tracking over multiple reporting periods. In the absence of a material surprise or a catalyst that significantly changes the Earnings trajectory, existing shareholders at current prices tend not to prompt sharp share price moves on confirmatory updates.

 

Financial Performance: Ten Months to April 2026

Cryosite's unaudited financial results for the 10-month period to April 30, 2026 show revenue of AUD 13.8 million, up 22% from AUD 11.3 million in the prior corresponding period. EBITDA increased 28% to AUD 3.4 million, with EBITDA margin expanding by one percentage point to 25%. EBIT grew 37% to AUD 2.7 million, and NPAT increased 28% to AUD 1.9 million, with NPAT margin also expanding by one percentage point to 14%.

The company noted a record EBITDA month in April 2026, which the Board attributed to increasing Operating Leverage across the Business as infrastructure utilisation improves. Core storage, inbound, and outbound service revenues remain the primary driver of performance and continue to grow, with early operational volumes in May 2026 indicating that the April momentum is being maintained.

The NPAT margin expansion to 14% despite additional interest costs associated with the Adderley Street freehold Acquisition — a AUD 9.5 million asset acquired in November 2025, funded through operating cash flows — highlights the company's ability to grow margins while simultaneously investing in growth infrastructure. As the Adderley Street facility is progressively activated and contributes to revenue, management expects further margin expansion.

 

Facilities Expansion: Ferndell Street and Adderley Street

Cryosite has completed construction of an expansion to its primary 2 degrees Celsius to 8 degrees Celsius cool room at its Ferndell Street facility in South Granville, NSW, under budget and on time, fully funded through operating cash flows. Quality validation is underway, with full commissioning expected in the coming weeks. The expansion increases primary cool room capacity by more than 100%, directly supporting growing clinical trial Volume Demand.

The Adderley Street freehold Warehouse — a 2,100-square-metre facility acquired for AUD 9.5 million in November 2025 — is also on track and on budget, with initial commissioning works expected to conclude prior to June 30, 2026. The client-led fit-out phase is scheduled to commence immediately thereafter. Client discussions regarding utilisation of Adderley Street are progressing, with initial opportunities focused on new market segments including medical devices and pallet storage, which would further diversify Cryosite's client base and revenue streams.

 

Balance Sheet and Refinancing

In May 2026, Cryosite refinanced its National Australia Bank debt facility on a four-year term extending to 2030. The refinancing provides greater certainty and long-term financial flexibility for the company as it executes its growth strategy. Consistent with the debt repayment strategy communicated to shareholders, the company has accelerated principal repayments and has reduced the outstanding balance to approximately AUD 5.6 million, representing approximately AUD 1.0 million in repayments made to date. The company has no other debt obligations.

The combination of an extended facility term, accelerated repayments, and a strong Operating Cash Flow profile positions Cryosite's balance sheet conservatively for a company in the midst of a material facilities expansion cycle. The company also successfully lodged its first Research and Development Tax Incentive claim during the period, which is expected to provide an additional recurring cash flow benefit going forward.

 

Operational and Sector Context

Cryosite operates within the global life sciences Supply chain as a specialist in outsourced clinical trial and biological depot services. Its service suite covers the importation, receipt, storage, distribution, and reverse logistics of specialised ambient, cold, frozen, ultra-frozen, and cryogenic clinical trial, pharmaceutical, and biological products. The Ultra-Frozen and Cryogenic segment has performed particularly well, supported by increasing activity in Biologics, cell and gene therapies, and mRNA-based medicines — all high-growth therapeutic categories.

The company achieved EcoVadis Gold Medal status during FY26, recognising its commitment to sustainability and responsible business practices — a credential that is increasingly relevant to large pharmaceutical and biotech clients when selecting clinical trial logistics partners. Cost pressures from global supply chain disruptions related to ongoing Middle East conflict have been substantially managed through fixed fuel Surcharge arrangements with key suppliers, delivering benefits to clients and protecting margins.

 

Conclusion

Cryosite's 10-month trading update for FY2026 confirms a business delivering consistent revenue and earnings growth, expanding margins, and investing in infrastructure capacity that is yet to be fully reflected in its financial results.. As the Adderley Street facility activates and the expanded Ferndell Street cool room commences contributing, the next 12 months will test whether Cryosite can sustain and extend the growth rates evidenced in the current year-to-date numbers.